Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Twist Bioscience Corporation (TWST) Tops Q2 EPS by 8c, Offers Guidance
May 5, 2023 7:39 AM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($1.04), $0.08 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $56.64 million.
GUIDANCE:
Twist Bioscience Corporation sees Q3 2023 revenue of $60-61... More
